Últimas noticias sobre Nomad Foods (NYSE:NOMD) Bolsa

Nomad Foods

Nomad Foods Ltd is a packaged foods company that is involved in the business of manufacturing and distribution of branded frozen foods in Western Europe. The company manufactures and markets frozen food products such as fish, vegetables, poultry, Ice Cream and ready meals like pizza. It sells its products through large grocery retailers under the brand Birds Eye in the United Kingdom and Ireland, Findus in Italy, France, Spain, and Scandinavia, and Iglo in Germany and other continental markets. The company operates through a single segment being Frozen. The majority of the revenue is generated from the United Kingdom.

Earnings

Long Ideas

News

Pre-Market Outlook

Markets

Trading Ideas

MSEX

NOMD

OKTA

Aquí tienes cinco acciones estadounidenses que podrían llamar la atención de los inversores este lunes: CRC, NOMD, MSEX, MRC y OKTA.

5 acciones en el foco este lunes: CRC, NOMD, MSEX, MRC y OKTA

Nomad Foods Ltd

<a href="https://x.com/blueorcainvest/status/1944783917917061578" title="https://x.com/blueorcainvest/status/1944783917917061578">https://x.com/blueorcainvest/status/1944783917917061578</a>

Short Sellers

Legal

HSAI

Blue Orca Capital Posts On X "1/As we predicted in our report issued three months ago, on Friday Hesai ($HSAI) lost the blacklisting lawsuit against the U.S. Department of Defense designating it a "Chinese military company." ...."

Arthur J. Gallagher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AJG#NYSE">AJG</a>) has outperformed the market over the past 15 years by 5.77% on an annualized basis producing an average annual return of 18.14%. Currently, Arthur J. Gallagher has a market capitalization of $79.42 billion. 
Buying $1000 In AJG: If an investor had bought $1000 of AJG stock 15 years ago, it would be worth $12,479.56 today based on a price of $310.54 for AJG at the time of writing.
<h3>Arthur J. Gallagher's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1752507912_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $1000 Invested In Arthur J. Gallagher 15 Years Ago Would Be Worth Today

Jefferies analyst Julien Dumoulin-Smith maintains SolarEdge Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEDG#NASDAQ">SEDG</a>) with a Underperform and raises the price target from $10 to $18.

Price Target

Analyst Ratings

SEDG

Jefferies Maintains Underperform on SolarEdge Technologies, Raises Price Target to $18

<a href="https://x.com/BarakRavid/status/1944773192402309488" title="https://x.com/BarakRavid/status/1944773192402309488">https://x.com/BarakRavid/status/1944773192402309488</a>

Macro Economic Events

Politics

Global

Economics

General

Global Affairs Correspondent for Axios Barak Ravid Posts On X "Two sources told me they had reason to believe the plan was likely to include long-range missiles that could reach targets deep inside Russian territory, including Moscow. However, neither was aware of any final decision"

Big bank earnings season kicks off Tuesday, July 15, with key industry heavyweight JPMorgan Chase &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JPM#NYSE">JPM</a>), Citigroup Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/C#NYSE">C</a>) and Wells Fargo Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WFC#NYSE">WFC</a>) headlining a crucial reporting day for financials, as Wall Street eyes a rebound in quarterly profits fueled by stronger net interest income and <a href="https://www.benzinga.com/topic/expert-ideas">healthy capital markets activity.</a>
Here's what to expect as the second-quarter 2025 numbers roll in before the bell.
<h3 class="wp-block-heading">Bank Profits Growth Expected </h3>
Wall Street expects a strong quarter for major banks, with JPMorgan Chase &amp; Co. forecast to deliver earnings per share (EPS) of $4.48 in the second quarter, a modest 1.8% increase from $4.40 a year ago. Revenue is projected at $44.17 billion, reflecting a pullback from last year's $50.2 billion.
Citigroup is expected to post more robust growth, with EPS projected to rise 6.6% year over year to $1.62 from $1.52. Revenue is also expected to improve slightly to $20.89 billion, up 3.9% from last year's Q2.
Wells Fargo is forecast to earn $1.40 per share, a 5.3% increase over the prior-year quarter. Revenue is expected to remain flat at $20.78 billion, indicating stable core banking performance despite macroeconomic headwinds.
BlackRock Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLK#NYSE">BLK</a>), although not a traditional bank, is poised for a solid performance in asset management, with EPS expected to reach $10.80, representing a 4.2% increase over last year. Revenues are projected to be $5.34 billion, representing an 11% increase.
Other names in focus include Bank of New York Mellon Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BK#NYSE">BK</a>), expected to post EPS of $1.76 on $4.83 billion in revenue, and State Street Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STT#NYSE">STT</a>), which is projected to earn $2.37 per share on $3.35 billion in revenue—both reflecting ongoing resilience in custody and asset servicing segments.
<figure class="wp-block-table is-style-stripes"> 
<table class="has-fixed-layout">
<thead>
<tr>
<th>Bank Name</th>
<th>Estimated EPS</th>
<th>Estimated Revenue</th>
</tr>
</thead>
<tbody>
<tr>
<td>JPMorgan Chase</td>
<td>4.48</td>
<td>$44.17B</td>
</tr>
<tr>
<td>Citigroup</td>
<td>1.62</td>
<td>$20.89B</td>
</tr>
<tr>
<td>Wells Fargo</td>
<td>1.40</td>
<td>$20.78B</td>
</tr>
<tr>
<td>BlackRock</td>
<td>10.80</td>
<td>$5.34B</td>
</tr>
<tr>
<td>Bank of New York Mellon</td>
<td>1.76</td>
<td>$4.83B</td>
</tr>
<tr>
<td>State Street</td>
<td>2.37</td>
<td>$3.35B</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Source: <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent&amp;t=be2bearmibe3na1">Benzinga Pro</a></figcaption></figure>
<h2 class="wp-block-heading">Banks To Step Up Shareholder Returns</h2>
The positive earnings outlook follows banks passing the Federal Reserve's June stress tests with ease, prompting widespread dividend hikes.
The median dividend per share across major banks rose 7%, with standouts like Goldman Sachs Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GS#NYSE">GS</a>) lifting its quarterly payout 33% to $4.00.
JPMorgan raised its dividend by 7% to $1.50 and authorized a massive $50 billion stock buyback program.
Citigroup boosted its dividend by 7% and continues its $20 billion multi-year repurchase plan.
<h2 class="wp-block-heading">Analyst Views: Where's The Opportunity?</h2>
Goldman Sachs analyst Richard Ramsden said Wells Fargo and Bank of America Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAC#NYSE">BAC</a>) offer the best earnings upside for investors heading into 2026.
He sees Bank of America's net interest income (NII) growing 7% annually through 2026, outperforming large bank peers, driven by stronger loan growth, favorable asset sensitivity and lower deposit costs. "We view BAC&#8217;s current ~1.5x 2026E price-to-tangible book value as attractive," Ramsden said.
For Wells Fargo, the recent removal of its asset cap opens the door to deposit growth, capital markets expansion and cost savings. Ramsden believes these factors could boost earnings by as much as 19% and push return on tangible common equity (ROTCE) to as high as 17.3%.
Bank of America analyst Ebrahim Poonawala echoed bullish sentiment, saying the sector could see &#8220;positive EPS revisions and further stock re-rating&#8221; if capital expenditures and client activity pick up.
He flagged Citigroup, Wells Fargo, and Goldman Sachs as offering the best risk-reward among money center banks.
<h2 class="wp-block-heading">What's At Stake For Investors?</h2>
With the Financial Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLF#NYSE">XLF</a>) up more than 8% year-to-date, bank stocks have already benefited from a more stable rate environment and strong capital positions.
However, any surprises in loan demand, expense growth, or trading revenue could quickly swing sentiment.
Tuesday&#8217;s results will set the tone for the rest of earnings season and could determine whether banks still have room to run, or whether Wall Street has already priced in the rebound.
Read now: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/07/46381861/us-stocks-to-buy-in-q3-2025-wall-street">Bank Of America Loves These 8 Stocks For Third Quarter—And Says To Dump These 2 Fast</a></li>
</ul>

Previews

JPMorgan, Citi To Kick Off Bank Earnings As Wall Street Sees Profit Boom

DA Davidson analyst Manuel Navas maintains Civista Bancshares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CIVB#NASDAQ">CIVB</a>) with a Buy and lowers the price target from $27 to $26.

CIVB

DA Davidson Maintains Buy on Civista Bancshares, Lowers Price Target to $26

TROO

TROOPS Shares Halted On Circuit Breaker To The Upside, Stock Now Up 246.2%

Reuters Reports White House Official Says President Trump Means He Will Impose 100% Tariffs On Russia, Secondary Sanctions On Other Countries That Buy Oil From Russia If A Deal Isn't Struck In 50 Days

<a href="https://x.com/i/broadcasts/1rmGPygYmaQJN" title="https://x.com/i/broadcasts/1rmGPygYmaQJN">https://x.com/i/broadcasts/1rmGPygYmaQJN</a>

President Trump In A Meeting With The Secretary General Of NATO, Says Trade Is "Great For Settling Wars"; Will Talk To Countries On Tariffs; Open To Trade Talks Including To Europe; EU Coming Over To Discuss Trade; Trade Deals Made

<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="900" height="600" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/14081604/BlueFocus-0714-900x600-1.png" alt="" class="wp-image-15738" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/14081604/BlueFocus-0714-900x600-1.png 900w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/14081604/BlueFocus-0714-900x600-1-300x200.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/14081604/BlueFocus-0714-900x600-1-768x512.png 768w" sizes="(max-width: 900px) 100vw, 900px" /></figure>
China's leading provider of marketing services is joining a growing tide of Shanghai- and Shenzhen-traded companies making second listings in Hong Kong
<h4 class="wp-block-heading">Key Takeaways:</h4>
<ul class="wp-block-list">
<li>BlueFocus has filed for a Hong Kong IPO, boasting its status as China's largest and the world's 10th biggest provider of marketing services</li>
<li>The company gets 80% of its revenue from Chinese firms targeting foreign buyers, but that business is undermining its bottom line due to extremely low margins</li>
</ul>
Who says only manufacturers can make IPOs in Hong Kong to complement their current listings on China's domestic A-share markets in Shanghai and Shenzhen?
Such dual listings have become some of Hong Kong's biggest IPOs this year, led by names like electric vehicle battery (EV) giant CATL, which raised $35.3 billion ($4.5 billion) in May, and top condiment maker Haitian, which raised HK$10.1 billion in June. But now, leading marketing services provider&nbsp;BlueFocus Intelligent Communications Group Co. Ltd.&nbsp;(300058.SZ) is aiming to break that monopoly with its own planned Hong Kong IPO.
BlueFocus is one of China's oldest providers of marketing services, set up in 1996. It's also the world's 10th&nbsp;biggest provider of such services, making it the lone Chinese company among the global top 10, which includes such powerhouses as&nbsp;WPP&nbsp;(WPP.L) and&nbsp;Omnicom&nbsp;(OMC.US), according to its Hong Kong&nbsp;<a href="https://www1.hkexnews.hk/app/sehk/2025/107472/documents/sehk25062501329.pdf">listing document</a>&nbsp;filed last week.
The company's financials reveal some notable trends, including the huge amounts of money that Chinese companies are spending on campaigns targeting overseas customers. Such spending accounted for 80% of BlueFocus' revenue last year, and that part of the business is growing far faster than its business for marketing services aimed at domestic consumers.
The company is also notable for its razor-thin margins that are well below its global peers, which it attributes to its growing focus on the intensely competitive global marketplace. As a result of that operating model, BlueFocus has been drifting back and forth between the red and the black in the last four years – a trend that looks likely to continue unless it can figure out how to operate its global marketing services business more efficiently.
The company is quite well known in Chinese advertising and PR circles, becoming one of the first to list on the Nasdaq-style ChiNext board in Shenzhen in 2010, just a year after the board's launch. Anyone savvy enough to buy those early shares has done quite well, with the stock up nearly five times since then, currently valuing the company at 23 billion yuan ($3.2 billion).
But even after such gains, BlueFocus' Shenzhen-listed shares currently trade at a price-to-sales (P/S) ratio of just 0.39 – quite anemic for this kind of industry leader and high-growth company that has averaged nearly 30% revenue growth in each of the last three years. That lack of investor enthusiasm is global, with WPP trading at an even lower 0.31, and Omnicom higher, though still not very impressive at 0.92.
BlueFocus' fundraising is unlikely to break the $1 billion mark, but could still raise hundreds of millions of dollars, judging from its current market cap and trio of relatively large underwriters including Huatai International, Guotai Junan and China Renaissance.
The company will use part of the funds to accelerate its recent global expansion that has given it offices in U.S., Vietnam, Thailand, Indonesia and Singapore. It will likely use those offices not only to serve its Chinese clients, but also to look for local business as it tries to compete with the global majors. That could become increasingly important as Chinese companies continue to rein in their spending due to a weak domestic economy.
<h4 class="wp-block-heading">Revenue starts to decline</h4>
Despite its less attractive margins and bottom line, there's no question that BlueFocus' top line revenue has posted strong growth over the last three years. That includes a 15.6% rise last year to 60.8 billion yuan from 52.6 billion yuan in 2023. But we should point out that rate was down sharply from the 43% growth it reported in 2023. And in a similarly worrisome sign, BlueFocus' revenue began to contract in the first quarter of this year, falling nearly 10% to 14.3 billion yuan from 15.8 billion yuan a year earlier, according to&nbsp;<a href="https://www.szse.cn/disclosure/listed/bulletinDetail/index.html?8c2df248-c0bf-4473-98f1-cc02c233054c">its filing</a>&nbsp;with the Shenzhen Stock Exchange.
The company didn't provide any explanation for the decline in its report. But much of the weakness probably came from its home China market, where companies have been curbing their spending as their growth stalls and consumer demand weakens. Reflecting that, the company's revenue from domestic marketing services tumbled nearly 30% last year to 8.1 billion yuan, though that was partly offset by a slight rise in revenue from domestic advertising services.
BlueFocus' global revenue breakdown provides an interesting snapshot of what markets Chinese companies are targeting, and helps to explain why Beijing may be eager to avoid an escalation of its trade war with the U.S. BlueFocus said that 42% of its customer spending targeting global markets last year was aimed at the U.S., while the second-largest market was Europe with a far smaller 15%.
The company's recent slip into revenue contraction is worrisome when you consider BlueFocus' extremely thin margins, giving it very little wiggle room to operate profitably. Its cost of revenue, mostly from payments to platforms like Google, Facebook and TikTok, equaled 97.5% of its revenue last year, giving it a gross margin of just 2.5% for the year. What's more, that figure has been coming down steadily lately, falling from 4.7% in 2022 to 3.4% in 2023.
The company blamed the high cost of advertising on major internet platforms for its thin margins. It said the problem was especially acute outside China, where it had very little bargaining power to negotiate better prices with giants like Google and TikTok. Still, we should point out the company's gross margins are still well below the roughly 17% for WPP and even higher 19% for Omnicom.
The bottom line is that BlueFocus needs to find a way to operate more profitably, though it could have trouble squeezing more money from its core Chinese clients due to the nation's weakening economy. It could potentially offset some of that weakness by looking for customers outside China, which explains the recent move to open new global offices. But its chances for success in those markets seem relatively small, since it will have to compete against both the global majors and many smaller local players who are far more familiar with local conditions.

Asia

Equities

IPOs

Opinion

BlueFocus Eyes Hong Kong IPO Amid Dual Listings Boom

Health insurer Elevance Health Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELV#NYSE">ELV</a>) is scheduled to release its second quarter 2025 financial <a href="https://www.benzinga.com/pressreleases/25/07/b46233308/elevance-health-to-hold-conference-call-and-webcast-to-discuss-second-quarter-2025-results-on-july" target="_blank" rel="noreferrer noopener">results on July 17</a>.
Analysts estimate adjusted earnings of $9.197 per share on sales of $48.24 billion, <a target="_blank" href="https://www.benzinga.com/pro/feature/newsfeed" rel="noreferrer noopener">as per data from Benzinga Pro</a>.
UnitedHealth Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) has been the first major health insurer to report quarterly earnings for several quarters. However, this quarter, the insurance giant will release its second quarter 2025 financial <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/b45734284/unitedhealth-group-announces-earnings-release-date" rel="noreferrer noopener">results on July 29</a>.
As it&#8217;s the biggest player in the industry, Forbes writes that analysts and investors often use its results to gauge the sector&#8217;s overall health.
Also Read: <a href="https://www.benzinga.com/trading-ideas/movers/25/07/46280387/unitedhealth-centene-hit-hard-by-guidance-shock-trumps-medicaid-push" target="_blank" rel="noreferrer noopener">UnitedHealth, Centene Hit Hard By Guidance Shock, Trump&#8217;s Medicaid Push</a>
All eyes will be on the sector after Centene Corp&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) withdrawal of its 2025 GAAP and adjusted diluted EPS guidance, which stems from its initial review of 2025 industry data from Wakely, an <a target="_blank" href="https://www.benzinga.com/trading-ideas/movers/25/07/46222916/centenes-guidance-withdrawal-spooks-sector-oscar-health-stock-falls" rel="noreferrer noopener">independent actuarial firm</a>.
While withdrawing its comprehensive EPS guidance, Centene has reaffirmed its&nbsp;fiscal year 2025 adjusted EPS&nbsp;to be greater than $7.25, aligning with the consensus of $7.23.
UnitedHealth suspended its 2025 outlook in May, citing that care activity <a target="_blank" href="https://www.benzinga.com/25/05/45373368/unitedhealth-stock-plunges-names-new-ceo-suspends-2025-guidance" rel="noreferrer noopener">continued to accelerate</a>.
Earlier in July, managed healthcare service provider under the Medicaid and Medicare programs, Molina Healthcare, Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>), issued preliminary second-quarter results and lowered its full-year 2025 earnings outlook, citing rising medical costs across its Medicaid, Medicare,&nbsp;<a target="_blank" href="https://www.benzinga.com/markets/guidance/25/07/46273556/molina-healthcare-says-higher-medical-cost-trends-bite-cuts-profit-guidance" rel="noreferrer noopener">and state marketplace businesses</a>.
The company expects Q2 adjusted earnings of approximately $5.50 per share—slightly below earlier forecasts—due to expected cost pressures that will persist into the second half of the year.
As a result, Molina cut its full-year 2025 adjusted EPS guidance to $21.50 -$22.50, down from at&nbsp;least $24.50&nbsp;previously. The new forecast reflects a consolidated pre-tax margin just under 4%, at the low end of the company&#8217;s long-term target.
Forbes <a target="_blank" href="https://www.forbes.com/sites/brucejapsen/2025/07/14/eyes-on-elevance-health-not-unitedhealth-as-first-to-report-earnings/" rel="noreferrer noopener">adds</a> Centene&#8217;s announcement is just the latest in a series of updates from health insurers who, over the past two years, have had a hard time managing the costs of people enrolled in government-subsidized health plans.
Price Action: UNH stock is down 1.29% at $300.19 at the last check on Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/movers/25/07/46394267/why-is-workhorse-stock-tumbling-on-monday" target="_blank" rel="noreferrer noopener">Workhorse Stock Tanks On Merger Talks With Private EV Maker</a></li>
</ul>
Image: Shutterstock

Large Cap

Health Care

Movers

streetTRACKS Dow Jones U.S. Large Cap Value Index Fund

Elevance Steps In As UnitedHealth Delays — Will It Set The Tone For Insurers?

DA Davidson analyst Peter Heckmann maintains SS&amp;C Technologies Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SSNC#NASDAQ">SSNC</a>) with a Buy and raises the price target from $94 to $98.

SSNC

DA Davidson Maintains Buy on SS&C Technologies Hldgs, Raises Price Target to $98

In an era where brick-and-mortar retailers are struggling to maintain their footing amid the rapid rise of e-commerce giants, Best Buy Co., Inc.&#8216;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBY#NYSE">BBY</a>) recent downgrade by Piper Sandler highlights the ongoing challenges faced by <a href="https://www.benzinga.com/topic/retailers">traditional electronics retailers.</a>
The Best Buy Analyst: <a href="https://www.benzinga.com/analyst-stock-ratings/analyst/58b96e17b85e930001592a16/peter-keith">Analyst Peter Keith</a> downgraded the rating from Overweight to Neutral, while reducing the price target from $82 to $75.
The Best Buy Thesis: While there is consumer awareness about the Windows 10 End of Life in October, this may not drive PC demand, Keith said in the downgrade note.
Check out <a href="https://www.benzinga.com/analyst-stock-ratings">other analyst stock ratings</a>.
Microsoft Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) provides instructions on how users can upgrade from Windows 10 to Windows 11 for free and several PC manufacturers have indicated that upgrades are already taking place, he added.
Best Buy's appliance sales have "significantly underperformed" those of Home Depot Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HD#NYSE">HD</a>) and Lowe&#8217;s Companies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LOW#NYSE">LOW</a>) over the past three years, and Costco Wholesale Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COST#NASDAQ">COST</a>) has become "more aggressive on appliance services," the analyst wrote.
Best Buy's Consumer Electronics category has comped -10% over the past six years, underscoring a lack of innovation—especially in TVs. The analyst notes that Walmart's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMT#NYSE">WMT</a>) recent acquisition of Vizio could further disrupt the market, as the company leverages high-margin Retail Media revenue from Vizio's growing install base to subsidize TV sales, potentially selling units at a loss or even offering them free to new Walmart+ members.
BBY Price Action: Best Buy Co shares were down 3.08% at $69.58 at the time of publication on Monday, <a href="https://www.benzinga.com/pro/" target="_blank" rel="noreferrer noopener">according to Benzinga Pro</a>.
Read More: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/earnings/25/06/45907713/furniture-retailer-lovesac-ends-best-buy-partnership-issues-weak-forecast">Furniture Retailer Lovesac Ends Best Buy Partnership, Issues Weak Forecast</a></li>
</ul>
Photo: Shutterstock

Analyst Color

Downgrades

COST

MSFT

Why Best Buy's Appliance Sales Can't Keep Up With Rivals

RYET

Ruanyun Edai Technology Shares Halted On Circuit Breaker To The Downside, Stock Now Down -80.4%

<a href="https://www.bloomberg.com/news/articles/2025-07-14/ice-cream-makers-pledge-to-remove-artificial-colors-by-2028?embedded-checkout=true">https://www.bloomberg.com/news/articles/2025-07-14/ice-cream-makers-pledge-to-remove-artificial-colors-by-2028?embedded-checkout=true</a>

JJSF

'Ice Cream Makers Pledge to Remove Artificial Colors by 2028'- Bloomberg

Ming Shing Group Shares Halted On Circuit Breaker To The Downside, Stock Now Down -15.6%

TROOPS Shares Resume Trade

BitMine Immersion Technologies Inc (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/BMNR#AMEX">BMNR</a>) shares are trading higher Monday after the company provided an update on its Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>) <a href="https://www.benzinga.com/pressreleases/25/07/n46390264/bitmine-immersion-now-holds-approximately-500-million-of-ethereum-to-advance-its-ethereum-treasury">treasury strategy</a>.
What Happened: BitMine announced that it&#8217;s now holding a total of $163,142 ETH, the native cryptocurrency of the Ethereum blockchain. The company said its total holdings are now valued at more than $500 million, which is more than 100% of the company&#8217;s PIPE proceeds. 
BitMine closed on its initial private placement of $250 million on July 9. Fundstrat's Tom Lee was also appointed chairman of the company's board, which has helped spark significant investor interest in companies adopting ETH strategies. 
Before the deal was announced, BitMine had a market cap of just $25.86 million and shares had fallen around 45% since the start of the year.&nbsp;BitMine had a market cap of approximately $2.10 billion as of Friday&#8217;s market close, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
&#8220;Since closing on the&nbsp;$250 million&nbsp;private placement, we have surpassed&nbsp;$500 million&nbsp;in&nbsp;Ethereum&nbsp;holdings, which validates our mission to increase our stake in the&nbsp;Ethereum&nbsp;network,&#8221;&nbsp;Lee said on Monday. 
Ethereum was up 2.51% over a 24-hour period, trading at approximately $3,063 at the time of publication. 
BMNR Price Action: <a href="http://benzinga.com/quote/bmnr" target="_blank" rel="noreferrer noopener">BitMine shares</a> were up 13.7% at $46.19 at the time of publication Monday, according to <a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/07/46389605/why-are-bitcoin-ethereum-xrp-dogecoin-suddenly-skyrocketing">Why Are Bitcoin, Ethereum, XRP, Dogecoin Suddenly Skyrocketing?</a></li>
</ul>
Photo: alfernec/Shuttertsock.com

$ETH

BMNR

BitMine Immersion Technologies Stock Is Soaring: What's Going On?

PTC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTC#NASDAQ">PTC</a>) has outperformed the market over the past 10 years by 5.75% on an annualized basis producing an average annual return of 17.16%. Currently, PTC has a market capitalization of $22.24 billion. 
Buying $1000 In PTC: If an investor had bought $1000 of PTC stock 10 years ago, it would be worth $4,838.41 today based on a price of $184.85 for PTC at the time of writing.
<h3>PTC's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1752507014_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning PTC Stock In The Last 10 Years

Sonnet BioTherapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SONN#NASDAQ">SONN</a>) stock surged Monday amid high trading volume following news of a transformative business combination with Rorschach I, backed by Atlas Merchant Capital and Paradigm. 
The deal will create Hyperliquid Strategies Inc., a public cryptocurrency treasury company holding around 12.6 million HYPE tokens—worth $583 million—plus $305 million in cash, for a total assumed value of $888 million.
The new entity will remain Nasdaq-listed under a new ticker and be led by Bob Diamond (Chairman) and David Schamis (CEO). Major crypto investors including Galaxy Digital, Pantera Capital, and D1 Capital are participating. Sonnet will become a subsidiary of Hyperliquid Strategies, continue biotech R&amp;D (e.g., SON-1010), and raise $5.5 million via private placement. 
Shareholders will receive a contingent value right (CVR) tied to Sonnet's legacy biotech assets, which remain open to partnership deals.
In April, Sonnet BioTherapeutics released safety results of SON-1010 (IL12-FHAB) at the highest dose combined with atezolizumab in the Phase 1b/2a trial in adult patients with advanced solid tumors or platinum-resistant <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/g44645634/sonnets-son-1010-demonstrates-a-strong-safety-profile-in-combination-with-atezolizumab-for-treatme" rel="noreferrer noopener">ovarian cancer (the SB221 study)</a>.
Based on feedback from a formal evaluation by the Safety Review Committee (SRC) for the SB221 study, the study can now advance to the expansion phase.
This phase will study the preliminary effect of the combination at the MTD before proceeding to a Phase 2a randomized comparison with the standard of care.
Price Action: SONN stock is up 151% at $12.98 at the last check on Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/07/46388763/nokia-adds-new-developer-tools-on-google-cloud-marketplace" target="_blank" rel="noreferrer noopener">Nokia Adds New Developer Tools On Google Cloud Marketplace</a></li>
</ul>

Biotech

SONN

Why Is Sonnet BioTherapeutics Stock Trading Higher On Monday?

Press Releases

Nomad Foods to Present at 27th Annual ICR Conference on January 14, 2025

Nomad Foods Provides 2025 Guidance Ahead of Presentation at the 27th Annual ICR Conference

Dividends

Nomad Foods Declares Quarterly Dividend Increase

Nomad Foods to Report Fourth Quarter and Full Year 2024 Financial Results on Monday, March 3, 2025

Nomad Foods Reports Fourth Quarter and Full Year 2024 Financial Results and Raises Full-Year 2025 Earnings Outlook

Nomad Foods Annual Report Available to Shareholders

Nomad Foods to Report First Quarter 2025 Financial Results on Thursday, May 8, 2025

Nomad Foods Declares Quarterly Dividend

Nomad Foods Reports First Quarter 2025 Financial Results

Nomad Foods to Present at the Deutsche Bank dbAccess Global Consumer Conference on June 4, 2025

Comments

Nomad Foods

Noticias

Últimas noticias sobre Nomad Foods (NYSE:NOMD) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL